Company news
Resverlogix Corp. news in 2012
Resverlogix Corp.'s news releases, calls and decks from 2012, newest first.
Resverlogix Initiates Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
October 16, 2012
Resverlogix Completes Enrollment In ASSURE Trial
September 26, 2012
Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease
August 28, 2012
Resverlogix Secures $25 Million, Five-Year Term Loan
August 27, 2012
Resverlogix Establishes Clinical & Scientific Advisory Board to Support the Clinical Development of RVX-208 and Other Bromodomain Inhibitors in Neurodegenerative Diseases
July 16, 2012
Resverlogix Completes Dosing of RVX-208 in SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
May 9, 2012
Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
April 23, 2012
Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action
April 19, 2012
Resverlogix to Present at The 14th Annual BIO CEO & Investor Conference
February 8, 2012
Resverlogix Enters Into Equity Distribution Agreement
January 19, 2012